{"pmid":32347761,"title":"The Danger of Neglecting Melanoma during the COVID-19 Pandemic.","text":["The Danger of Neglecting Melanoma during the COVID-19 Pandemic.","Due to the COVID-19 pandemic, planned medical and surgical activities are being postponed. For the dermatology community, this interruption to the healthcare system can lead to delays in the diagnosis and treatment of melanoma. Neglecting melanoma during this crisis can result in increased mortality, morbidity and healthcare costs. With the COVID-19 pandemic evolving and no clear solutions in sight, it is time for the prospective evaluation of teledermatology. However, dermatologists should be cautious and continue seeing patients with pigmented lesions in person due to the necessity of early surgical intervention.","J Dermatolog Treat","Gomolin, Tamar","Cline, Abigail","Handler, Marc Zachary","32347761"],"abstract":["Due to the COVID-19 pandemic, planned medical and surgical activities are being postponed. For the dermatology community, this interruption to the healthcare system can lead to delays in the diagnosis and treatment of melanoma. Neglecting melanoma during this crisis can result in increased mortality, morbidity and healthcare costs. With the COVID-19 pandemic evolving and no clear solutions in sight, it is time for the prospective evaluation of teledermatology. However, dermatologists should be cautious and continue seeing patients with pigmented lesions in person due to the necessity of early surgical intervention."],"journal":"J Dermatolog Treat","authors":["Gomolin, Tamar","Cline, Abigail","Handler, Marc Zachary"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347761","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1080/09546634.2020.1762844","keywords":["covid-19","delayed diagnosis","melanoma","public health","telemedicine"],"topics":["Prevention"],"weight":1,"_version_":1666138495391891457,"score":9.490897,"similar":[{"pmid":32468229,"title":"Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt.","text":["Melanoma Screening Days During the Coronavirus Disease 2019 (COVID-19) Pandemic: Strategies to Adopt.","Melanoma is one of the most common cancers, with an increasing incidence worldwide. Disease stage represents the most important prognosis factor; therefore, early diagnosis is essential for melanoma patients' survival rates. Following the outbreak in China, the coronavirus disease 2019 (COVID-19) pandemic has spread all over the world and the majority of dermatological visits have been postponed. These measures could cause a delay in melanoma diagnosis and management leading to an increase of morbidity, mortality and healthcare costs. Herein we propose an alternative model of skin cancer screening and the organization of screening campaigns in order to detect malignant lesions early during this emergency period.","Dermatol Ther (Heidelb)","Villani, Alessia","Fabbrocini, Gabriella","Costa, Claudia","Scalvenzi, Massimiliano","32468229"],"abstract":["Melanoma is one of the most common cancers, with an increasing incidence worldwide. Disease stage represents the most important prognosis factor; therefore, early diagnosis is essential for melanoma patients' survival rates. Following the outbreak in China, the coronavirus disease 2019 (COVID-19) pandemic has spread all over the world and the majority of dermatological visits have been postponed. These measures could cause a delay in melanoma diagnosis and management leading to an increase of morbidity, mortality and healthcare costs. Herein we propose an alternative model of skin cancer screening and the organization of screening campaigns in order to detect malignant lesions early during this emergency period."],"journal":"Dermatol Ther (Heidelb)","authors":["Villani, Alessia","Fabbrocini, Gabriella","Costa, Claudia","Scalvenzi, Massimiliano"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468229","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s13555-020-00402-x","keywords":["dermatoscopy","early detection","melanoma","prevention","screening","skin cancer"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668167109951094785,"score":310.668},{"pmid":32362041,"title":"Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model.","text":["Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model.","The coronavirus COVID-19 pandemic, which emerged in Wuhan, China several months ago,(1) has led to large-scale lockdown in many countries around the world, including Spain. Uncertainty about the duration of these measures led us to consider the potential impact of diagnostic delays due to the paralyzation of certain health procedures and services on the prognosis of patients with melanoma.","J Eur Acad Dermatol Venereol","Tejera-Vaquerizo, Antonio","Nagore, Eduardo","32362041"],"abstract":["The coronavirus COVID-19 pandemic, which emerged in Wuhan, China several months ago,(1) has led to large-scale lockdown in many countries around the world, including Spain. Uncertainty about the duration of these measures led us to consider the potential impact of diagnostic delays due to the paralyzation of certain health procedures and services on the prognosis of patients with melanoma."],"journal":"J Eur Acad Dermatol Venereol","authors":["Tejera-Vaquerizo, Antonio","Nagore, Eduardo"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32362041","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jdv.16555","keywords":["coronavirus","early diagnosis","melanoma","prognosis","quarantine"],"locations":["Wuhan","China","Spain"],"countries":["China","Spain"],"countries_codes":["CHN|China","ESP|Spain"],"topics":["Prevention"],"weight":1,"_version_":1666138495531352067,"score":185.11304},{"pmid":32502288,"title":"Melanoma defies 'lockdown': ongoing detection during Covid-19 in central London.","text":["Melanoma defies 'lockdown': ongoing detection during Covid-19 in central London.","The COVID-19 pandemic has presented significant challenges for Dermatology services, particularly the diagnosis and management of malignant melanoma (MM). Early detection and definitive surgical treatment are key to improving MM prognosis, and in England there is a suspected skin cancer referral pathway that facilitates specialist Dermatology assessment within two weeks. Here, we describe the impact of COVID-19 on MM detection, based on data from the a Dermatology Department in central London.","Clin Exp Dermatol","Schauer, A A","Kulakov, E L","Martyn-Simmons, C L","Bunker, C B","Edmonds, E","32502288"],"abstract":["The COVID-19 pandemic has presented significant challenges for Dermatology services, particularly the diagnosis and management of malignant melanoma (MM). Early detection and definitive surgical treatment are key to improving MM prognosis, and in England there is a suspected skin cancer referral pathway that facilitates specialist Dermatology assessment within two weeks. Here, we describe the impact of COVID-19 on MM detection, based on data from the a Dermatology Department in central London."],"journal":"Clin Exp Dermatol","authors":["Schauer, A A","Kulakov, E L","Martyn-Simmons, C L","Bunker, C B","Edmonds, E"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502288","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ced.14324","locations":["England","London","London"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1668804508718727169,"score":181.09142},{"pmid":32478867,"title":"Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.","text":["Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.","During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >/=T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >/=T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.","Cancer","Baumann, Brian C","MacArthur, Kelly M","Brewer, Jerry D","Mendenhall, William M","Barker, Christopher A","Etzkorn, Jeremy R","Jellinek, Nathaniel J","Scott, Jeffrey F","Gay, Hiram A","Baumann, John C","Manian, Farrin A","Devlin, Phillip M","Michalski, Jeff M","Lee, Nancy Y","Thorstad, Wade L","Wilson, Lynn D","Perez, Carlos A","Miller, Christopher J","32478867"],"abstract":["During the coronavirus disease 2019 (COVID-19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID-19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID-19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID-19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early-stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID-19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors >/=T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors >/=T2b should be prioritized, but a 1-month to 2-month delay is unlikely to worsen disease-specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic."],"journal":"Cancer","authors":["Baumann, Brian C","MacArthur, Kelly M","Brewer, Jerry D","Mendenhall, William M","Barker, Christopher A","Etzkorn, Jeremy R","Jellinek, Nathaniel J","Scott, Jeffrey F","Gay, Hiram A","Baumann, John C","Manian, Farrin A","Devlin, Phillip M","Michalski, Jeff M","Lee, Nancy Y","Thorstad, Wade L","Wilson, Lynn D","Perez, Carlos A","Miller, Christopher J"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478867","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cncr.32969","keywords":["merkel cell carcinoma","mohs surgery","basal cell carcinoma","coronavirus disease 2019 (covid-19)","cutaneous squamous cell carcinoma","melanoma","radiotherapy","skin cancer","treatment delays"],"locations":["Merkel"],"topics":["Prevention"],"weight":1,"_version_":1668437835182505984,"score":157.46452},{"pmid":32434789,"title":"Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.","text":["Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.","BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic.","J Immunother Cancer","Serzan, Michael T","Kumar, Princy N","Atkins, Michael B","32434789"],"abstract":["BACKGROUND: Immune checkpoint inhibitors (ICIs) can produce specific immune-related adverse events including pneumonitis. The impact of ICI therapy on the severity of acute coronavirus infection symptomatology warrants further exploration. CASE PRESENTATION: We report a 65-year-old man diagnosed with stage IV melanoma who developed pulmonary and brain metastases and was treated with bilateral craniotomies followed by combined nivolumab and ipilimumab immunotherapy. He developed early-onset severe dyspnea associated with acute coronavirus HKU1 (non-COVID-19) infection, with diffuse pneumonitis evidenced by ground glass opacification on CT scan. He was treated with steroids leading to resolution of pneumonitis on repeat imaging, suggesting an exacerbated immune-mediated toxicity. CONCLUSION: We report the first case of a patient with melanoma with severe and reversible diffuse pneumonitis in association with coronavirus HKU1 following combined nivolumab and ipilimumab immunotherapy. Although we do not have data on the impact of ICI therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatology, a possible interaction should be considered when deciding on dosing in patients with possible SARS-CoV-2 exposure or when evaluating patients with presumed ICI-related pneumonitis during the COVID-19 pandemic."],"journal":"J Immunother Cancer","authors":["Serzan, Michael T","Kumar, Princy N","Atkins, Michael B"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434789","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000898","keywords":["case reports","immunomodulation","immunotherapy","melanoma"],"e_drugs":["Steroids","Nivolumab","Ipilimumab"],"topics":["Treatment"],"weight":1,"_version_":1667521393798938624,"score":150.6997}]}